Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as C$11.68 and last traded at C$11.25, with a volume of 300 shares traded. The stock had previously closed at C$11.25.
Fennec Pharmaceuticals Stock Performance
The firm has a market capitalization of C$218.50 million, a PE ratio of -191.93 and a beta of 0.25. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The stock has a 50-day moving average price of C$8.68 and a 200-day moving average price of C$8.82.
Insider Activity at Fennec Pharmaceuticals
In related news, Senior Officer Robert Christopher Andrade bought 8,220 shares of the stock in a transaction dated Monday, June 2nd. The stock was bought at an average cost of C$6.99 per share, with a total value of C$57,433.14. Also, Director Jeffrey Hackman bought 15,000 shares of the stock in a transaction dated Monday, May 19th. The shares were bought at an average cost of C$9.77 per share, with a total value of C$146,580.00. Insiders sold a total of 28,076 shares of company stock valued at $242,518 over the last three months. 16.20% of the stock is owned by insiders.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Read More
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
